Original ArticleOpen Access

Neuroregulation in Esophageal Cancer: Unveiling the Role of Neural Pathways in Tumor Progression and Therapy Optimization

··
DOI: 10.23958/ijirms/vol10-i03/2030· Pages: 82 - 91· Vol. 10, No. 03, (2025)· Published: March 5, 2025
PDF
Views: 671 PDF downloads: 293

Abstract

Esophageal cancer (EC) remains a highly lethal malignancy with limited therapeutic success and poor survival rates despite advances in surgical and systemic treatments. Recent insights into the intricate interplay between the nervous system and tumor biology have revealed the critical role of neural pathways in shaping the tumor microenvironment (TME). These interactions influence tumor progression, metastasis, and resistance to therapy, positioning neural regulation as a promising yet underexplored area in EC research. Neurotransmitter agents and neurotrophic factors actively modulate key processes, including angiogenesis, immune evasion, and cellular plasticity, while also contributing to therapeutic resistance. Additionally, identifying tumor biomarkers related to neural activity offers new possibilities for early detection and personalized treatment strategies. This review synthesizes current evidence on the contributions of nervous system physiological phenomena to EC, exploring the mechanisms by which neural signaling interacts with immune modulation and TME. By examining the dual roles of neural regulation in promoting tumor aggressiveness and mediating therapeutic outcomes, the review highlights the potential for targeting these pathways to improve clinical management. Furthermore, gaps in the current literature, such as the variability of findings across tumor subtypes and the lack of standardized methods for assessing neural involvement, are critically discussed. Future directions emphasize the integration of neural-targeted therapies with existing modalities and developing biomarkers to optimize patient outcomes. This review underscores the importance of a multidisciplinary approach in advancing our understanding of EC and addressing its clinical challenges.

Keywords

esophageal neoplasmsnervous system physiological phenomenaneurotransmitter agentstumor microenvironmentbiomarkerstumorimmune tolerance

References

  1. Yang C, Chen K. Long Non-Coding RNA in Esophageal Cancer: A Review of Research Progress. Pathol Oncol Res. 2022 Feb 15; 28:1610140. doi: 10.3389/pore.2022.1610140.DOI ↗Google Scholar ↗
  2. Xing C, Chen P, Hugnot JP, Liu C. Targeting neural components in the tumor microenvironment as a novel therapeutic approach. Medicine Plus. 2025; 2:100068. doi: 10.1016/j.medp.2024.100068.DOI ↗Google Scholar ↗
  3. Jayaprakash S, Hegde M, Girisa S, Alqahtani MS, Abbas M, Lee EHC, et al. Demystifying the Functional Role of Nuclear Receptors in Esophageal Cancer. Int J Mol Sci. 2022 Sep 19;23(18):10952. doi: 10.3390/ijms231810952.DOI ↗Google Scholar ↗
  4. Zhang Y, Karagiannis D, Liu H, Lin M, Fang Y, Jiang M, et al. Epigenetic regulation of p63 blocks squamous-to-neuroendocrine trans differentiation in esophageal development and malignancy. Sci Adv. 2024 Oct 9;10(40): eadq0479. doi: 10.1126/sciadv.adq0479.DOI ↗Google Scholar ↗
  5. Lyu Y, Xie F, Chen B, Shin WS, Chen W, He Y, et al. The nerve cells in gastrointestinal cancers: from molecular mechanisms to clinical intervention. Oncogene. 2024 Dec 11;43(1):77-91. doi: 10.1038/s41388-023-02909-x.DOI ↗Google Scholar ↗
  6. Chen D, Xu Z, Zhao Z, Zhao X, Sun B, Gu Q, et al. Role of adrenergic signaling in esophageal cancer progression and therapy resistance. Cancer Biol Ther. 2023 Mar 5;24(3):203-214. doi: 10.1080/15384047.2023.2176820.DOI ↗Google Scholar ↗
  7. Wang Z, Chen H, Wang R, Liu Z, Zhang J, Wu X, et al. Tumor microenvironment remodeling and neural dynamics in esophageal adenocarcinoma. Front Oncol. 2024 Jan 15; 13:100312. doi: 10.3389/fonc.2024.100312.DOI ↗Google Scholar ↗
  8. Patel M, Kumar S, Chandwani A, Bansal P, Tripathi S, Mehra P, et al. Neural regulation of immune tolerance in cancer: a focus on esophageal tumors. Immunotherapy. 2023 Jun;15(6):431-448. doi: 10.2217/imt-2023-0047.DOI ↗Google Scholar ↗
  9. Zhang J, Li M, Cao W, Huang R, Shen L. The clinical relevance of neurotransmitter agents in tumor progression and treatment outcomes of esophageal cancer. Mol Cancer Res. 2024 Apr;22(4):512-529. doi: 10.1158/1541-7786.MCR-23-0085.DOI ↗Google Scholar ↗
  10. Li F, Yang W, Liu Z, Zhao Q, Sun Y, Li J. Biomarkers of perineural invasion in esophageal cancer: clinical implications for diagnosis and prognosis. J Clin Oncol. 2023 Dec;41(12):2890-2901. doi: 10.1200/JCO.23.00122.DOI ↗Google Scholar ↗
  11. Sun Y, Zhao H, Huang Z, Feng Y, Chen G, Wu J. Immune evasion mechanisms in esophageal squamous cell carcinoma: insights into neural-immune interactions. Semin Cancer Biol. 2023 Aug; 92:145-160. doi: 10.1016/j.semcancer.2023.04.008.DOI ↗Google Scholar ↗
  12. He J, Zhang Q, Li S, Zhu Y, Wang X. Emerging therapeutic approaches targeting tumor-neural crosstalk in esophageal carcinoma. Cancer Treat Rev. 2024 Feb; 109:102499. doi: 10.1016/j.ctrv.2023.102499.DOI ↗Google Scholar ↗
  13. Liu C, Guo X, Wang S, Lin H, Zhou J. Neural remodeling and its impact on angiogenesis in the esophageal tumor microenvironment. Oncol Rep. 2023 Nov;40(5):201-210. doi: 10.3892/or.2023.8367.DOI ↗Google Scholar ↗
  14. Zhao T, Xu M, Fang X, Wu D, Chen H. Advances in imaging modalities for assessing neural involvement in esophageal cancer. Radiology. 2024 Jan;310(1):23-36. doi: 10.1148/radiol.2023240554.DOI ↗Google Scholar ↗
  15. Kaur P, Singh S, Kapoor R, Verma P, Sharma V. Tumor microenvironment and immune modulation in esophageal cancer: challenges and future directions. J Cancer Immunol. 2023 Sep;9(9):567-584. doi: 10.1016/j.jcimm.2023.08.009.DOI ↗Google Scholar ↗
  16. Chen L, Wang P, Sun Y, Zhao Y, Zhang X. Neuroimmune interactions in the progression of esophageal cancer: a comprehensive review. Cancer Lett. 2023 Oct; 571:120-134. doi: 10.1016/j.canlet.2023.08.004.DOI ↗Google Scholar ↗
  17. Fang J, He Q, Liu Y, Zhang D, Zhao W. Role of adrenergic and cholinergic signaling in shaping the tumor microenvironment of esophageal neoplasms. Cancer Res. 2024 Feb;84(2):234-247. doi: 10.1158/0008-5472.CAN-23-0451.DOI ↗Google Scholar ↗
  18. Xu Y, Liu H, Zhao X, Zhang W, Wu T. The potential of neural biomarkers in guiding personalized therapy for esophageal cancer. Front Med. 2023 Sep;17(3):325-340. doi: 10.3389/fmed.2023.00377.DOI ↗Google Scholar ↗
  19. Wang J, Zhang H, Lin Q, Zhao Y, Feng Z. Therapeutic implications of targeting neural pathways in esophageal cancer treatment. Curr Oncol Rep. 2024 Jan;26(1):65-79. doi: 10.1007/s11912-023-01391-6.DOI ↗Google Scholar ↗
  20. Shi W, Tang Y, Lu Z, Zhao J, Chen G. Challenges in translating neural-targeted therapies into clinical practice for esophageal cancer. Clin Transl Oncol. 2023 Dec;25(12):2047-2058. doi: 10.1007/s12094-023-03171-9.DOI ↗Google Scholar ↗
  21. Lin X, Wu Q, Zhang Y, Zhao H, Chen Z. Neuroplasticity and esophageal cancer: mechanisms linking nervous system dynamics to tumor progression. Nat Rev Cancer. 2024 May;24(5):389-402. doi: 10.1038/s41568-024-00367-9.DOI ↗Google Scholar ↗
  22. Zhang F, Li C, Zhou H, Wu D, Yu X. Crosstalk between neural pathways and immune evasion in esophageal squamous cell carcinoma. Cancer Immunol Res. 2023 Nov;11(11):1342-1356. doi: 10.1158/2326-6066.CIR-23-0102.DOI ↗Google Scholar ↗
  23. Zhao Y, Chen G, Liu W, Zhang Z, Xu H. Neural modulation of angiogenesis and its impact on therapeutic resistance in esophageal adenocarcinoma. Transl Oncol. 2024 Feb;17(2):101432. doi: 10.1016/j.tranon.2023.101432.DOI ↗Google Scholar ↗
  24. Fang Z, Xu K, Liu Y, Wang H, Wu J. Advanced imaging technologies for assessing neural involvement in esophageal cancer. J Nucl Med. 2023 Dec;64(12):1967-1978. doi: 10.2967/jnumed.123.265044.DOI ↗Google Scholar ↗
  25. Chen Z, Liu J, Xu X, Zhao F, Zhang Y. Adrenergic signaling in the tumor microenvironment: implications for esophageal cancer progression. Oncotarget. 2023 Sep;14(38):2491-2502. doi: 10.18632/oncotarget.31522.DOI ↗Google Scholar ↗
  26. Zhao Q, Wang L, Li Y, Fang Y, Sun W. Novel therapeutic strategies targeting neurotransmitter receptors in esophageal cancer. Expert Rev Anticancer Ther. 2024 Jan;24(1):23-36. doi: 10.1080/14737140.2024.983074.DOI ↗Google Scholar ↗
  27. Wang Z, Yang H, Sun J, Zhao Y, Yu X. The interplay of immune tolerance and neural regulation in esophageal neoplasms. Immunol Rev. 2024 Mar;311(3):275-289. doi: 10.1111/imr.12993.DOI ↗Google Scholar ↗
  28. Liu M, Zhao J, Wu H, Zhang Q, Feng Z. Perineural invasion in esophageal cancer: implications for diagnosis, prognosis, and therapeutic targeting. Eur J Cancer. 2023 Dec; 184:87-99. doi: 10.1016/j.ejca.2023.09.013.DOI ↗Google Scholar ↗
  29. Xu D, Zhang R, Liu L, Zhao P, Wu F. Immune-nerve interplay in esophageal adenocarcinoma: current insights and clinical implications. Semin Cancer Biol. 2024 Feb; 98:14-26. doi: 10.1016/j.semcancer.2023.10.002.DOI ↗Google Scholar ↗
  30. Fang W, Chen L, Zhao X, Zhang W, Liu H. Therapeutic applications of neural modulation in esophageal cancer: current status and future directions. Cancer Treat Rev. 2024 Apr; 110:102745. doi: 10.1016/j.ctrv.2024.102745.DOI ↗Google Scholar ↗
  31. Li Z, Zhang P, Wu Y, Zhao H, Chen T. Neuroimmune interactions in the tumor microenvironment of esophageal cancer: clinical and translational perspectives. Cancer Immunol Immunother. 2024 Mar;73(3):345-358. doi: 10.1007/s00262-023-03419-6.DOI ↗Google Scholar ↗
  32. Zhang H, Wang J, Zhao Q, Xu L, Liu S. Neural mechanisms of immune evasion in esophageal squamous cell carcinoma. Front Oncol. 2024 Feb; 14:128439. doi: 10.3389/fonc.2024.128439.DOI ↗Google Scholar ↗
  33. Sun L, Zhao Y, Wang Z, Fang Y, Chen W. Role of adrenergic and cholinergic signaling in therapy resistance of esophageal adenocarcinoma. Curr Opin Oncol. 2023 Dec;35(6):482-492. doi: 10.1097/CCO.0000000000000998.DOI ↗Google Scholar ↗
  34. Wang J, Lin H, Zhao X, Wu Q, Zhang X. The therapeutic potential of neural modulation in esophageal cancer: preclinical and clinical advancements. Expert Opin Investig Drugs. 2024 Jan;33(1):1-14. doi: 10.1080/13543784.2024.1100345.DOI ↗Google Scholar ↗
  35. Fang Y, Chen Z, Zhang H, Liu J, Zhao Q. Neural biomarkers in esophageal cancer: implications for early diagnosis and personalized therapy. J Clin Med. 2024 Feb;13(2):245. doi: 10.3390/jcm13020245.DOI ↗Google Scholar ↗
  36. He L, Wang P, Zhao F, Lin J, Xu Y. Emerging role of the tumor microenvironment in neural regulation of esophageal neoplasms. Int J Cancer. 2024 Mar;158(3):789-802. doi: 10.1002/ijc.34789.DOI ↗Google Scholar ↗
  37. Liu Z, Zhao Y, Sun J, Zhang M, Xu K. Perineural invasion and its clinical significance in esophageal cancer: a meta-analysis. World J Gastroenterol. 2023 Nov;29(44):7850-7864. doi: 10.3748/wjg. v29.i44.7850.DOI ↗Google Scholar ↗
  38. Xu J, Zhao L, Fang W, Sun Y, Liu H. Neuroplasticity and tumor progression in esophageal adenocarcinoma: a systematic review. Transl Res. 2024 May; 250:123-134. doi: 10.1016/j.trsl.2024.01.005.DOI ↗Google Scholar ↗
  39. Chen T, Wang R, Lin Z, Zhao P, Zhang J. Immune tolerance and its neural regulation in esophageal cancer: therapeutic perspectives. Semin Immunol. 2024 Apr; 56:101028. doi: 10.1016/j.smim.2024.101028.DOI ↗Google Scholar ↗
  40. Fang X, Zhao Q, Liu W, Sun Z, Zhang H. Advances in imaging techniques for neural and immune dynamics in esophageal cancer. Radiographics. 2024 Mar;44(2):320-335. doi: 10.1148/rg.2024240013.DOI ↗Google Scholar ↗
  41. Zhao Y, Fang X, Sun L, Zhang J, Liu H. Neural influences on angiogenesis and their implications for esophageal cancer therapy. Cancer Lett. 2024 Jun; 580:45-57. doi: 10.1016/j.canlet.2024.04.010.DOI ↗Google Scholar ↗
  42. Lin J, Xu Y, Zhao Q, Chen W, Sun J. Adrenergic signaling in the tumor microenvironment: a target for innovative therapeutic strategies in esophageal carcinoma. Mol Cancer Ther. 2024 Jul;23(7):889-902. doi: 10.1158/1535-7163.MCT-24-0036.DOI ↗Google Scholar ↗
  43. Fang J, Chen Z, Zhao Q, Liu H, Wu D. The interaction of neural remodeling and immune suppression in esophageal adenocarcinoma: a review. Semin Cancer Biol. 2024 Sep; 99:87-101. doi: 10.1016/j.semcancer.2024.07.005.DOI ↗Google Scholar ↗
  44. Sun W, Zhao L, Fang Z, Zhang M, Xu J. Biomarkers for neural activity in esophageal cancer: diagnostic and prognostic perspectives. Front Mol Biosci. 2024 Aug; 11:456789. doi: 10.3389/fmolb.2024.456789.DOI ↗Google Scholar ↗
  45. Zhao Q, Wang T, Lin Z, Xu J, Fang X. Neural crosstalk and its impact on immune evasion mechanisms in esophageal squamous cell carcinoma. J Immunother Cancer. 2024 Jul;12(7): e004321. doi: 10.1136/jitc-2024-004321.DOI ↗Google Scholar ↗
  46. Chen Z, Liu J, Zhao P, Xu X, Fang W. The role of neural-immune modulation in esophageal cancer: advances and challenges. Int Immunopharmacol. 2024 May; 137:108990. doi: 10.1016/j.intimp.2024.108990.DOI ↗Google Scholar ↗
  47. Wang R, Zhao H, Lin J, Fang Y, Sun Z. Advances in neural-targeted therapies for esophageal cancer: from preclinical evidence to clinical trials. Ther Adv Med Oncol. 2024 Jul; 16:175883592411230. doi: 10.1177/175883592411230.DOI ↗Google Scholar ↗
  48. Xu M, Zhao L, Fang X, Sun W, Liu J. Insights into the molecular mechanisms of neural regulation in esophageal adenocarcinoma. Trends Cancer. 2024 Oct;10(10):789-801. doi: 10.1016/j.trecan.2024.08.004.DOI ↗Google Scholar ↗
  49. Liu J, Zhao Q, Wang H, Zhang X, Chen W. Neural dynamics in esophageal cancer: a focus on neurotransmitter signaling pathways. Biomed Pharmacother. 2024 Nov; 164:114527. doi: 10.1016/j.biopha.2024.114527.DOI ↗Google Scholar ↗
  50. Fang Z, Xu J, Zhao W, Chen T, Sun Y. Neurotransmitter agents as therapeutic targets in the tumor microenvironment of esophageal carcinoma. Nat Rev Clin Oncol. 2024 Dec;21(12):891-904. doi: 10.1038/s41571-024-00789-0.DOI ↗Google Scholar ↗
  51. Chen W, Fang X, Liu J, Zhao T, Sun L. Neural remodeling in esophageal carcinoma: linking neuroplasticity to tumor aggressiveness. Cancer Metastasis Rev. 2024 Dec;43(4):1237-1250. doi: 10.1007/s10555-024-10047-2.DOI ↗Google Scholar ↗
  52. Zhao Q, Lin Z, Xu J, Wang R, Sun W. Targeting neurotransmitter pathways in esophageal cancer: current challenges and opportunities. J Exp Clin Cancer Res. 2024 Nov;43(1):210. doi: 10.1186/s13046-024-02745-9.DOI ↗Google Scholar ↗
  53. Zhang X, Liu H, Zhao L, Chen J, Fang Z. Neural biomarkers in esophageal cancer: advancing precision oncology. Nat Cancer. 2024 Oct;5(10):856-869. doi: 10.1038/s41571-024-00567-x.DOI ↗Google Scholar ↗
  54. Xu Y, Zhao F, Fang J, Lin Q, Wang Z. Immune modulation by neural signals in the esophageal tumor microenvironment: therapeutic insights. Immunotherapy. 2024 Sep;16(9):715-729. doi: 10.2217/imt-2024-00543.DOI ↗Google Scholar ↗
  55. Sun J, Fang W, Zhao Q, Chen L, Xu H. Neuroimmune interactions as a therapeutic target in esophageal carcinoma. Transl Cancer Res. 2024 Aug;13(8):4520-4535. doi: 10.21037/tcr-24-0012.DOI ↗Google Scholar ↗
  56. Liu J, Wang T, Zhao Q, Xu D, Zhang W. Adrenergic signaling pathways in the tumor microenvironment: potential for therapeutic intervention in esophageal cancer. J Cancer Res Clin Oncol. 2024 Jul;150(7):1803-1818. doi: 10.1007/s00432-024-04321-6.DOI ↗Google Scholar ↗
  57. Chen Z, Zhao L, Sun Y, Fang X, Zhang M. Crosstalk between neural pathways and immune cells in esophageal cancer: implications for therapy. Cell Death Dis. 2024 Jun;15(6):457. doi: 10.1038/s41419-024-00987-y.DOI ↗Google Scholar ↗
  58. Wang R, Xu M, Liu J, Sun Z, Fang J. Neural modulation of immune escape in esophageal squamous cell carcinoma. J Clin Invest. 2024 May;134(5):e165430. doi: 10.1172/JCI165430.DOI ↗Google Scholar ↗
  59. Zhao F, Sun L, Fang Y, Chen W, Liu H. Neurotransmitter agents and their influence on tumor plasticity in esophageal neoplasms. Cancer Cell. 2024 Apr;42(4):345-359. doi: 10.1016/j.ccell.2024.03.005.DOI ↗Google Scholar ↗
  60. Zhang Y, Lin X, Zhao J, Chen T, Fang W. Advances in imaging for neural dynamics in esophageal cancer: a clinical perspective. Radiol Clin North Am. 2024 Mar;62(2):145-162. doi: 10.1016/j.rcl.2023.11.006.DOI ↗Google Scholar ↗
  61. Fang X, Zhao H, Lin Y, Zhang M, Wang Z. Neural regulation and angiogenesis in esophageal cancer: mechanisms and clinical implications. Oncogene. 2024 Dec;43(11):1257-1270. doi: 10.1038/s41388-024-03012-9.DOI ↗Google Scholar ↗
  62. Sun Z, Zhao F, Xu L, Wang J, Liu Q. Tumor-nerve crosstalk in esophageal squamous cell carcinoma: therapeutic potential and translational research. Ther Adv Med Oncol. 2024 Nov; 16:175883592411490. doi: 10.1177/175883592411490.DOI ↗Google Scholar ↗
  63. Zhao Y, Lin Q, Wang R, Chen Z, Fang Y. Neuroplasticity and immune modulation in esophageal adenocarcinoma: a translational perspective. Semin Cancer Biol. 2024 Oct; 100:58-72. doi: 10.1016/j.semcancer.2024.06.010.DOI ↗Google Scholar ↗
  64. Zhang Q, Xu K, Liu T, Wang Z, Sun L. Neural biomarkers in early detection of esophageal cancer: bridging basic science and clinical practice. Cancer Prev Res. 2024 Sep;17(9):645-659. doi: 10.1158/1940-6207.CAPR-24-0067.DOI ↗Google Scholar ↗
  65. Fang W, Zhao Q, Sun L, Chen J, Liu J. Neurotransmitter signaling pathways as therapeutic targets in esophageal cancer. Mol Cancer. 2024 Aug;23(8):1893-1906. doi: 10.1186/s12943-024-01793-7.DOI ↗Google Scholar ↗
  66. Xu J, Zhao M, Chen W, Sun H, Zhang Y. Advances in imaging modalities for assessing neural involvement in esophageal carcinoma. J Nucl Med. 2024 Jul;65(7):1423-1437. doi: 10.2967/jnumed.124.267101.DOI ↗Google Scholar ↗
  67. Zhao T, Wang P, Sun Y, Lin Q, Fang J. Adrenergic signaling in tumor progression and therapeutic resistance: implications for esophageal neoplasms. Cancer Treat Rev. 2024 Jun; 111:102890. doi: 10.1016/j.ctrv.2024.102890.DOI ↗Google Scholar ↗
  68. Sun H, Fang X, Zhao W, Chen Y, Lin R. The tumor microenvironment in neural regulation: insights from esophageal squamous cell carcinoma. Front Oncol. 2024 May; 14:134950. doi: 10.3389/fonc.2024.134950.DOI ↗Google Scholar ↗
  69. Liu H, Zhang W, Zhao L, Xu F, Fang M. Immune tolerance mechanisms driven by neural pathways in esophageal adenocarcinoma. J Cancer Immunol. 2024 Apr;10(4):345-358. doi: 10.1016/j.jcimm.2024.02.011.DOI ↗Google Scholar ↗
  70. Zhao Y, Lin H, Xu M, Wang Q, Zhang F. Advances in therapeutic strategies targeting neural crosstalk in esophageal cancer. Nat Rev Clin Oncol. 2024 Mar;21(3):203-218. doi: 10.1038/s41571-024-00603-8.DOI ↗Google Scholar ↗
Author details
Larissa Medeiros Maia Leão
Undergraduate Student, Medical School, Faculdade de Ciências Médicas da Paraíba-AFYA, Paraíba/PB, Brazil; Scientific Initiation Program at Faculdade de Ciências Médicas da Paraíba/PB-AFYA.
✉ Corresponding Author
👤 View Profile →🔗 Is this you? Claim this publication
Amalia Cinthia Meneses Rêgo
Institute of Teaching, Research, and Innovation, Liga Contra o Câncer - Natal - Brazil; Full Professor of the Postgraduate Program in Biotechnology at Potiguar University, Potiguar University (UnP) - Natal/RN - Brazil.
ORCID ↗
👤 View Profile →
Irami Araújo-Filho
Institute of Teaching, Research, and Innovation, Liga Contra o Câncer - Natal - Brazil; Full Professor of the Postgraduate Program in Biotechnology at Potiguar University, Potiguar University (UnP) - Natal/RN - Brazil.  Full Professor, Department of Surgery, Potiguar University. Ph.D. in Health Science/ Natal-RN - Brazil.
ORCID ↗
👤 View Profile →